Donya Bazhan1, Mahmoud Shekari Khaniani2. 1. Department of Cellular & Molecular Biology, Islamic Azad University, Ahar Branch, Ahar, Iran. 2. Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract
BACKGROUND: Many lines of evidence suggest that arachidonic acid (AA)-based eicosanoid signaling pathway involved in development and progression of human cancers. Cytosolic phospholipase A2-α (cPLA2α) encoded by the PLA2G4A gene acts as an upstream regulator of eicosanoid signaling pathway through providing intracellular AA. The current study aimed to evaluate the effect of omega fatty acids on mRNA expression level of PLA2G4A in patients with gastric cancer (GC) and to assess the possible relation between its expression and clinicopathological features. METHODS: According to treatment strategy, 34 chemotherapy-naive patients were randomly divided into two groups including, treatment group I (17 subjects received cisplatin alone) and treatment group II (17 individuals received cisplatin plus omega fatty acids) in a double-blind manner. The gastric biopsies specimens were taken from subjects before and after treatment and then mRNA expression level of PLA2G4A was evaluated by quantitative real-time PCR procedure. RESULTS: The expression of the PLA2G4A gene at the protein level in the gastric biopsies samples was also determined by immunohistochemistry. Our findings revealed a significantly up-regulated expression of PLA2G4A mRNA in treatment group II after receiving cisplatin plus omega fatty acid compared to before treatment (P=0.003). In treatment group I, there was no significant difference in mRNA expression levels of PLA2G4A before and after treatment (P=0.790). We also found that mRNA expression of PLA2G4A in treatment group II was significantly associated with tumor size (P=0.007) and familial history (P=0.006). CONCLUSIONS: This study provides evidence that supplementation with omega fatty acids increases the mRNA expression level of PLA2G4A in patients with GC and may be crucial in guarding the cell from transformation and carcinogenesis.
BACKGROUND: Many lines of evidence suggest that arachidonic acid (AA)-based eicosanoid signaling pathway involved in development and progression of human cancers. Cytosolic phospholipase A2-α (cPLA2α) encoded by the PLA2G4A gene acts as an upstream regulator of eicosanoid signaling pathway through providing intracellular AA. The current study aimed to evaluate the effect of omega fatty acids on mRNA expression level of PLA2G4A in patients with gastric cancer (GC) and to assess the possible relation between its expression and clinicopathological features. METHODS: According to treatment strategy, 34 chemotherapy-naive patients were randomly divided into two groups including, treatment group I (17 subjects received cisplatin alone) and treatment group II (17 individuals received cisplatin plus omega fatty acids) in a double-blind manner. The gastric biopsies specimens were taken from subjects before and after treatment and then mRNA expression level of PLA2G4A was evaluated by quantitative real-time PCR procedure. RESULTS: The expression of the PLA2G4A gene at the protein level in the gastric biopsies samples was also determined by immunohistochemistry. Our findings revealed a significantly up-regulated expression of PLA2G4A mRNA in treatment group II after receiving cisplatin plus omega fatty acid compared to before treatment (P=0.003). In treatment group I, there was no significant difference in mRNA expression levels of PLA2G4A before and after treatment (P=0.790). We also found that mRNA expression of PLA2G4A in treatment group II was significantly associated with tumor size (P=0.007) and familial history (P=0.006). CONCLUSIONS: This study provides evidence that supplementation with omega fatty acids increases the mRNA expression level of PLA2G4A in patients with GC and may be crucial in guarding the cell from transformation and carcinogenesis.
Entities:
Keywords:
PLA2G4A; Phospholipase A2; gastric cancer (GC); omega fatty acids
Authors: Jillian N M Ilsley; Masako Nakanishi; Christopher Flynn; Glenn S Belinsky; Sylvain De Guise; John N Adib; Rick T Dobrowsky; Joseph V Bonventre; Daniel W Rosenberg Journal: Cancer Res Date: 2005-04-01 Impact factor: 12.701
Authors: Mei Dong; Michael Johnson; Anahita Rezaie; Jillian N M Ilsley; Masako Nakanishi; Melinda M Sanders; Faripour Forouhar; Joel Levine; David C Montrose; Charles Giardina; Daniel W Rosenberg Journal: Clin Cancer Res Date: 2005-03-15 Impact factor: 12.531
Authors: Patricia D Schley; Humberto B Jijon; Lindsay E Robinson; Catherine J Field Journal: Breast Cancer Res Treat Date: 2005-07 Impact factor: 4.872
Authors: Manish I Patel; Jaskirat Singh; Marzieh Niknami; Caroline Kurek; Mu Yao; Sasa Lu; Fiona Maclean; Nicholas J C King; Michael H Gelb; Kieran F Scott; Pamela J Russell; John Boulas; Qihan Dong Journal: Clin Cancer Res Date: 2008-12-15 Impact factor: 12.531